

Under the Paperwork Reduction Act of 1995, no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>					
Substitute for form 1449A/B PTO			<b>Complete if Known</b>		
			Application Number	10/582,124; Conf. No. 1776	
			Filing Date	May 10, 2007	
			First Named Inventor	Linda Greensmith	
			Art Unit	1628	
			Examiner Name	Christopher R. Stone	
Sheet	1	of	1	Attorney Docket Number	CytRx/012

<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication or Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (if known)				
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
<b>NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		BENN et al., "Putting the heat on ALS," <i>Nature Medicine</i> , 10(4):345-347 (2004).				
		CSARDI et al., "Pharmacokinetic study on a new antiischaemic agent (BRLP-42)", <i>Acta Physiologica Hungarica</i> , 82(4):321-326 (1994).				
		EUROPEAN EXTENDED SEARCH REPORT; August 28, 2009, European Application 08157425.3.				
		INTERNATIONAL SEARCH REPORT, February 28, 2005, PCT Publication WO 2005/041965.				
		KIERAN et al., "Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice," <i>Nature Medicine</i> , 10(4):402-405 (2004).				
		KURTHY et al., "Effect of BRX-220 against peripheral neuropathy and insulin resistance in Diabetic rat models," <i>Annals of the New York Academy of Sciences</i> , 967:482-489 (2002).				
		LOVE, "Arimoclomol delays progression in ALS mouse model," <i>Lancet Neurology</i> , 3(5):264 (2004).				
		TOTH et al., "Effect of bimoclomol 1 (N-(2-hydroxy-3-(1-piperidinyl) propoxy)-3 pyridine-carboximidoyl-chloride) on iminodipropionitrile-induced central effects," <i>Neurochemistry International</i> , 33(6):513-518 (1998).				
		VISY et al., "Enantioselective Plasma Protein Binding of Bimoclomol," <i>Chirality</i> , 14:638-642 (2002).				
Examiner Signature					Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.